
pmid: 21916999
AbstractCatheter‐related blood stream infections may be reduced by interdialytic locking with Taurolidine, a nontoxic antimicrobial agent. A formulation of 1.35% Taurolidine in 4% citrate (TC) is associated with a greater need for thrombolysis to maintain catheter patency than 5000 U/ml heparin. Our aim was to determine whether addition of 500 Units/ml of heparin to TC reduces the need for thrombolysis. TCH (1.35% taurolidine, 4% citrate and 500 U/ml heparin) was compared to TC and Heparin 5000 U/ml using retrospective data. Hundred and six adult hemodialysis patients with internal jugular tunnelled intravascular catheters using TCH were compared with 34 patients using TC and 34 patients using heparin 5000 U/ml respectively. Outcomes were time to first use of thrombolysis and bacteremia rates.TCH reduced the need for thrombolysis compared to TC (hazard ratio, 0.2; 95%CI: 0.06, 0.5; p < 0.001) and was not significantly different from heparin 5000 U/ml (hazard ratio, 1.4; 95%CI: 0.5, 3.9; p = 0.5). The bacteremia rates from all causes were 1.33, 1.22 and 3.25 per 1000 catheter‐ days (p < 0.001) in the TCH, TC and heparin groups respectively. Addition of 500 U/ml heparin to TC reduces the need for thrombolysis without increasing bacteremia and may achieve patency comparable to heparin 5000 U/ml.
Thiadiazines/therapeutic use, Adult, Male, Catheters, Anti-Infective Agents/therapeutic use, Bacteremia, Chronic/diagnosis, Kaplan-Meier Estimate, Risk Assessment, Citric Acid, Taurine/analogs & derivatives, Kidney Failure, Catheter-Related Infections/drug therapy, Renal Dialysis/adverse effects, Catheters, Indwelling, Drug Therapy, Thrombolytic Therapy/methods, Anti-Infective Agents, Double-Blind Method, Bacteremia/drug therapy, Indwelling/adverse effects, Vascular Patency/physiology, Humans, Catheters, Indwelling/adverse effects, Heparin/therapeutic use, Proportional Hazards Models, Aged, Equipment Contamination/prevention & control, Heparin, Citric Acid/therapeutic use, Incidence, Anticoagulants, Middle Aged, Kidney Failure, Chronic/diagnosis, Treatment Outcome, Anticoagulants/therapeutic use, Catheter-Related Infections, Combination, Linear Models, Equipment Contamination, Kidney Failure, Chronic, Drug Therapy, Combination, Female, Needs Assessment, Follow-Up Studies
Thiadiazines/therapeutic use, Adult, Male, Catheters, Anti-Infective Agents/therapeutic use, Bacteremia, Chronic/diagnosis, Kaplan-Meier Estimate, Risk Assessment, Citric Acid, Taurine/analogs & derivatives, Kidney Failure, Catheter-Related Infections/drug therapy, Renal Dialysis/adverse effects, Catheters, Indwelling, Drug Therapy, Thrombolytic Therapy/methods, Anti-Infective Agents, Double-Blind Method, Bacteremia/drug therapy, Indwelling/adverse effects, Vascular Patency/physiology, Humans, Catheters, Indwelling/adverse effects, Heparin/therapeutic use, Proportional Hazards Models, Aged, Equipment Contamination/prevention & control, Heparin, Citric Acid/therapeutic use, Incidence, Anticoagulants, Middle Aged, Kidney Failure, Chronic/diagnosis, Treatment Outcome, Anticoagulants/therapeutic use, Catheter-Related Infections, Combination, Linear Models, Equipment Contamination, Kidney Failure, Chronic, Drug Therapy, Combination, Female, Needs Assessment, Follow-Up Studies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 44 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
